[Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].

@article{Schreiber2014DiseaseMA,
  title={[Disease modification and duration of omalizumab treatment in patients with severe allergic asthma].},
  author={J. H. Schreiber and Matthias V Kopp and Simon Korn and Christian Taube and R. Buhl},
  journal={Pneumologie},
  year={2014},
  volume={68 3},
  pages={187-92}
}
BACKGROUND AND METHODS Omalizumab is a monoclonal anti-IgE-antibody that is used to treat severe allergic asthma. The aim of this review was to evaluate the available evidence in a panel of experts and to provide recommendations on therapy duration with omalizumab. RESULTS A direct or indirect interaction between omalizumab and IgE production seems likely… CONTINUE READING